Floatz logo

Chir-258

Hepatic Impairment

Novartis PharmaceuticalsPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Hepatic Impairment cohort.

Asset / SponsorPhaseRating
Efinopegdutide
Merck Sharp & Dohme LLC
Phase 2BB
Selvigaltin
Galecto Biotech AB
Phase 1/2CCC
Paliperidone Palmitate 3-Month Formulation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 1CC
Camizestrant
AstraZeneca
Phase 1CC
Carboplatin
Daiichi Sankyo
Phase 1CC

View all 38 →

Same molecule, other indications

Chir-258 is also rated in:

NeoplasmsDormant
B
Indicative ·
57 / 100
View asset →
Stage III Pancreatic CancerDormant
CCC
Indicative ·
54 / 100
View asset →
Breast CancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →